October 29, 2019 07:01 AM EDTUpdated 07:27 AM
Deals
R&D

No­var­tis' $111M bet on IL-17C drug turns sour — but Mor­phoSys, Gala­pa­gos will ex­plore op­tions

Amber Tong

Just a year af­ter No­var­tis bought its way in­to Mor­phoSys’ and Gala­pa­gos’ de­vel­op­ment pact for MOR106, the part­ners are writ­ing off the atopic der­mati­tis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times